LNTH
Lantheus Holdings IncNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$5.08B
P/E Ratio
22.90
EPS
$3.41
Beta
-0.13
52W High
$108.91
52W Low
$47.25
50-Day MA
$73.36
200-Day MA
$64.88
Dividend Yield
—
Profit Margin
15.10%
Forward P/E
14.10
PEG Ratio
0.61
About Lantheus Holdings Inc
Lantheus Holdings, Inc. develops, manufactures and markets diagnostic and therapeutic agents and products that assist physicians in the diagnosis and treatment of heart, cancer and other diseases worldwide. The company is headquartered in North Billerica, Massachusetts.
Fundamentals
| Revenue (TTM) | $1.54B |
| Gross Profit (TTM) | $941.95M |
| EBITDA | $382.31M |
| Operating Margin | 19.10% |
| Return on Equity | 21.40% |
| Return on Assets | 9.28% |
| Revenue/Share (TTM) | $22.84 |
| Book Value | $16.87 |
| Price-to-Book | 4.55 |
| Price-to-Sales (TTM) | 3.30 |
| EV/Revenue | 3.384 |
| EV/EBITDA | 12.93 |
| Quarterly Earnings Growth (YoY) | -77.10% |
| Quarterly Revenue Growth (YoY) | 4.00% |
| Shares Outstanding | $65.10M |
| Float | $57.81M |
| % Insiders | 2.04% |
| % Institutions | 109.25% |
Analyst Ratings
Consensus ($91.38 target)
2
Strong Buy9
Buy2
HoldData last updated: 4/8/2026